Blocking MEK-ERK-RSK2 signaling results in reduced activation of several transcriptional regulators of proliferative genes in tumor cells (e.g. melanomas and myeloma) and suppresses cell growth [39]. This evidence concerns the gene MAP2K7 and plasma cell myeloma.